Trial Profile
A Multicenter Postmarketing Study to Evaluate the Placental Transfer of Certolizumab Pegol in Pregnant Women Receiving Treatment With Cimzia (Certolizumab Pegol)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Jun 2019
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Spondylarthritis; Spondylitis
- Focus Pharmacokinetics
- Acronyms CRIB
- Sponsors UCB
- 25 Mar 2019 According to a UCB media release, the Health Canada has approved label updates in pregnancy and breastfeeding based on two pivotal pharmacokinetic studies (CRIB and CRADLE).
- 22 Mar 2018 Results published in the UCB Media Release
- 22 Mar 2018 According to an UCB media release, The approval of the CIMZIA label update is based on data from the post-marketing pharmacokinetic CRIB and CRADLE studies